Strategic partnerships Refeyn has established recent integrations with R&D Systems and Bio-Techne to combine mass photometry with charge heterogeneity analysis, creating a compelling cross-sell opportunity for customers seeking end-to-end molecular characterization workflows.

Expanded workflow The launch of integrated workflows for bispecific antibodies and biosimilars positions Refeyn as a solution for biopharma developers pursuing scalable, single-molecule resolution analytics, suggesting upsell potential to teams adopting complex biologics pipelines.

Product expansion New instruments such as MyMass and KaritroMP indicate a broader product footprint beyond core mass photometry, opening doors for sales to structural biology labs and viral vector characterization groups seeking rapid, reproducible QC and analysis.

Market momentum Strong industry recognition with Nobel Prize usage, hundreds of global installations, and ongoing media coverage signals growing credibility and demand, providing a favorable environment for expanding into larger research institutions and contract research organizations.

Executive transition Recent leadership change at the board level suggests potential for renewed strategic focus and sponsorship of larger deals; leverage relationships and governance channels to accelerate multi-year procurement opportunities and pilot programs.